LUCIA MARIA MATTEI DE ARRUDA CAMPOS

(Fonte: Lattes)
Índice h a partir de 2011
21
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Tipo de produção: conferenceObject ×

Resultados de Busca

Agora exibindo 1 - 10 de 23
  • conferenceObject
    Macrophage Activation Macrophage Activation Syndrome: A Severe and Frequent Manifestation of Acute Pancreatitis in Childhood-Onset Compared to Adult Systemic Lupus Erythematosus Patients
    (2014) SPELLING, Natali W.; OTSUZI, Carini I.; BARROS, Diego L.; SILVA, Mariana A. da; PEREIRA, Rosa M. R.; CAMPOS, Lucia M. A.; BORBA, Eduardo F.; BONFA, Eloisa; SILVA, Clovis A.
  • conferenceObject
    INVASIVE FUNGAL INFECTIONS SURVEY IN 852 CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: A MULTICENTER COHORT
    (2015) SILVA, M. F.; FERRIANI, M. P.; TERRERI, M. T.; PEREIRA, R. M.; MAGALHAES, C. S.; BONFA, E.; CAMPOS, L. M.; OKUDA, E. M.; APPENZELLER, S.; FERRIANI, V. P.; BARBOSA, C. M.; RAMOS, V. C.; LOTUFO, S.; SILVA, C. A.
  • conferenceObject
    Yellow Fever Vaccination in Brazil: Short-Term Safety in Pediatric Autoimmune Rheumatic Diseases
    (2018) AIKAWA, Nadia E.; BALBI, Verena A.; TONACIO, Adriana C.; SALLUM, Adriana M. E.; CAMPOS, Lucia M. A.; KOZU, Katia T.; VENDRAMINI, Margarete B.; FONTOURA, Nicole; SARTORI, Ana M. C.; ANTONANGELO, Leila; SILVA, Clovis A.; BONFA, Eloisa
  • conferenceObject
    Dyslipidemia in Juvenile Dermatomyositis: The Role of Disease Activity
    (2012) KOZU, Katia T.; SILVA, Clovis Artur; BONFA, Eloisa; SALLUM, Adriana M.; PEREIRA, Rosa M. R.; VIANA, Vilma S.; BORBA, Eduardo F.; CAMPOS, Lucia M. A.
  • conferenceObject
    Retinal vasculitis (RV) in pediatric population: case series
    (2020) GIAMPIETRO, Barbara; SOUTO, Fernanda Maria Silveira; TAKIUTI, Julia Tieme; CAMPOS, Lucia Maria Arruda; HIRATA, Carlos Eduardo; YAMAMOTO, Joyce H.
  • conferenceObject
    NUTRITIONAL ASSESSMENT, BODY COMPOSITION AND PHASE ANGLE IN JUVENILE DERMATOMYOSITIS PATIENTS
    (2023) PUGLIESE, Camila; KOZU, Katia T.; CAMPOS, Lucia M. A.; AIKAWA, Nadia E.; SILVA, Clovis A. A.; ELIAS, Adriana M.
  • conferenceObject
    A Brazilian Multicenter Study of 71 Children and Adolescents with Takayasu's Arteritis
    (2012) TERRERI, Maria Teresa; CLEMENTE, Gleice; SILVA, Clovis; SACCHETTI, Silvana; SALLUM, Adriana M.; CAMPOS, Lucia M. A.; SANTOS, Maria Carolina; SZTAJNBOK, Flavio; ALMEIDA, Rozana Gasparello de; FERRIANI, Virginia P.; BICA, Blanca E.; ROBAZZI, Teresa; BANDEIRA, Marcia; CAVALCANTI, Andre; LESSA, Marise; OLIVEIRA, Sheila K. Feitosa de; HILARIO, Maria Odete
    Background/Purpose: Takayasu’s arteritis is a chronic granulomatous disease that affects the vascular wall of the large arteries and can result in end organ damage. It is more prevalent in young women, but can also occur in the childhood. The disease is rare and there are few reports about the clinical features at this age. Our aim was to describe the clinical features of Takayasu’s arteritis in children and adolescents in our population. Methods: In this Brazilian multicenter retrospective study including 10 pediatric rheumatology centers we identified 71 children and adolescents with Takayasu’s arteritis. Patients’ demographic, clinical, laboratory, angiographic, therapeutic data and disease outcome were recorded. Results: Of the 71 patients, 51 (72%) were girls, with a mean age at onset of 9.2 years (range 4 months to 17.2 years); the average time to diagnosis was 1.2 years; and the mean follow-up time was 5.4 years. The most frequent angiographic type was type IV (41%) followed by type V (27%) and the abdominal aorta was the most affected vessel (63.4%). The main lesion was arterial stenosis (84.5% of patients). At initial presentation 80.6% of patients had increased acute phase reactants and 41% of patients had a positive Mantoux test. The predominant clinical symptoms at onset were constitutional (77.5%), followed by neurological (70.4%) and musculoskeletal symptoms (64.8%). The main cardiovascular manifestation was arterial hypertension (84.5%). At the final evaluation, neurological symptoms were predominant (22.7%) and decrease of peripheral pulses (66.7%) was the main cardiovascular manifestation. Sixty four (90.1%) patients were treated with corticosteroids, 30 patients (42.3%) with methotrexate as the first immunosuppressive treatment and 18 (25.4%) were treated with cyclophosphamide as initial therapy. Infliximab was used in only 4 patients throughout the follow-up. At the final evaluation, 55% of patients were in disease remission, 28% had active disease, 7% died and in 10% the outcome was unknown. Conclusion: Takayasu’s arteritis is a rare childhood disease. In this multicenter study we observed a high rate of disease remission, however prospective studies are needed in order to better define overall disease outcome.
  • conferenceObject
    Immunogenicity and Safety of Two Doses of Influenza A H1N1/2009 Vaccine in Young Autoimmune Rheumatic Diseases Patients Under 9 Years Old
    (2012) TRUDES, Guilherme; AIKAWA, Nadia E.; CAMPOS, Lucia M.; PEREIRA, Rosa M. R.; MORAES, Julio C. B.; RIBEIRO, Ana Cristina; MIRAGLIA, Joao; TIMENETSKY, Maria do Carmo S.; BONFA, Eloisa; SILVA, Clovis Artur
    Background/Purpose: In 2010 the Advisory Committee on Immunization Practices from the CDC recommended that all children should receive the rivalent seasonal influenza vaccine containing the A/California/7/2009 (H1N1)-like virus with a specific protocol of two doses in subjects under 9 years old. There is, however, no data regarding this vaccine immunogenicity and safety in young children with autoimmune rheumatic diseases (ARD). Methods: 42 ARD patients and 12 healthy controls were initially recruited. One juvenile idiopathic arthritis patient had typical uncomplicated febrile seizure after first dose and did not receive the second dose and 3 patients and one control did not complete the study. Therefore, 38 ARD patients [25 juvenile idiopathic arthritis, 5 juvenile dermatomyositis, 3 juvenile systemic lupus erythematosus, 3 juvenile scleroderma and 2 primary vasculitis] and 11 healthy children completed the study and received two doses of a non-adjuvanted preparation of influenza A/California/7/2009 (H1N1) virus-like vaccine. They were clinically evaluated before and 21 days after the second dose of vaccination and serology for anti-H1N1 antibody was performed by hemagglutination inhibition (HI) assay. Seroprotection and seroconversion rates, geometric mean titres (GMT) and factor increase (FI) in GMT (ratio of the GMT after vaccination to the GMT before vaccination) were calculated. Adverse events were also evaluated. Results: Current age (7 vs. 7.8 years, p=0.55) and female gender (76. vs. 63.6%, p=0.45) were comparable in ARD patients and controls. Five (13.2%) patients were not receiving any drug, 18 (47.4%) patients were under non-steroidal anti-inflammatory drugs and 11 (28.9%) under prednisone, with a median current dose of 15mg (4–40). Twenty-three (60.5%) were taking methotrexate, 6 (15.8%) cyclosporine, one (2.6%) azathioprine and 7 (18.4%) anti-TNF agents. Pre-vaccination seroprotection rates (p=1.0) and GMT (p=0.63) were comparable between patients and controls. Three weeks after immunization seroprotection (81.6 vs. 81.8%; p=1.0), seroconversion rates (81.6 vs. 90.9%; p=0.66), GMT (151.5 vs. 282.1, p=0.26) and the FI in GMT (16.7 vs. 36.3; p=0.226) were similar in patients and controls, with both groups achieving adequate response according to the European Medicines Agency and Food and Drug Administration standards. The analysis of the possible factors influencing seroconversion showed no difference in demographic data, leukocytes and lymphocytes count or frequency of immunosuppressive drugs use (including prednisone, methotrexate, cyclosporine, azathioprine and anti-TNF agents) between seroconverted and non-seroconverted patients (p> 0.05). No severe adverse events were observed. Conclusion: Two doses of the non-adjuvanted influenza A H1N1/2009 vaccination induced an effective antibody response in young children with ARD independent of demographic characteristics, lymphocytes count and immunosuppressive treatment. Adverse events were rarely observed suggesting vaccine recommendation for this group of patients. (ClinicalTrials.gov,#NCT01151644)
  • conferenceObject
    PULMONARY ABNORMALITIES IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
    (2015) VEIGA, C. S. da; COUTINHO, D. S.; NAKAIE, C. M. A.; CAMPOS, L. M. A.; SUZUKI, L.; LEONE, C.; SILVA, C. A.; RODRIGUES, J. C.
  • conferenceObject
    Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis
    (2020) BALBI, Verena; SILVA, Clovis; PEDROSA, Tatiana; PEREIRA, Rosa; CAMPOS, Lucia; LEON, Elaine; DUARTE, Nilo; CARVALHO, Valdemir; PASOTO, Sandra; ROSARIO, Debora; BRANDAO, Leticia; BONFA, Eloisa; AIKAWA, Nadia